EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, cilt.78, sa.12, ss.1973-1979, 2022 (SCI-Expanded)
Aim To compare survival outcomes, response rates, and adverse events (AEs) in proton pump inhibitor (PPI) user and nonuser patients with metastatic colorectal cancer (mCRC) treated with regorafenib.